Trabectedin for advanced mesenchymal chondrosarcoma with a specific gene fusion
Treatments studied
Part of Cancer clinical trials.
This trial tests trabectedin, a chemotherapy medicine, for people with advanced mesenchymal chondrosarcoma that carries a specific gene fusion (HEY1-NCOA2). It’s designed for cases that have worsened despite prior chemotherapy, aiming to shrink tumors or control disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 16 or older
- Your cancer diagnosis is confirmed by a biopsy and includes the HEY1-NCOA2 gene fusion
- Your cancer is advanced (locally advanced and/or has spread), and there must be measurable or trackable disease
- Your cancer has shown progression within the last 6 months on scans
- You’ve already had 1 prior chemotherapy treatment that included an anthracycline, and you’ve had no more than 3 total chemotherapy “lines” for advanced disease
- Your general health and organ tests must be good enough for treatment (including heart strength, blood counts, and liver/kidney function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies how well gemcitabine or trabectedin works for people with leiomyosarcoma that cannot be fully removed or has spread. It’s for tumors that have grown or worsened despite prior standard chemotherapy.
This Phase 3 trial tests trabectedin (in tTF-NGR study) for people with advanced or metastatic soft-tissue sarcoma whose first treatment with anthracycline drugs didn’t work (or can’t be used). It aims to see if this approach works better than the study comparison treatment, using tumor response and other safety outcomes.
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
Hear when a new Mesenchymal Chondrosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.